Efficacy and Safety Study of Tunodafil Hydrochloride Tablets in Erectile Dysfunction

This is a multicenter, randomized, double blind, placebo-controlled, parallel design study to evaluate the efficacy and safety of Tunodafil Hydrochloride Tablets in men with erectile dysfunction.

Inclusion Criteria: * \- Male subjects aged between 18 and 65 years (inclusive) diagnosed with Erectile Dysfunction (ED). * At Visit 1, subjects must have an International Index of Erectile Function-5 (IIEF-5) score ≤ 21, with a disease duration of at least 6 months. * Subjects must have a stable marital relationship or a stable female sexual partner for at least 3 months prior to screening and throughout the study period. * Subjects must agree to attempt sexual intercourse at least 4 times per visit cycle. * Subjects agree not to use any other ED treatments during the study, including PDE5 inhibitors, traditional Chinese medicine (including decoctions and patent medicines), or medical devices for ED treatment. * Subjects (and their partners) must have no plans for conception from the time of screening up to 3 months after the last dose, and must voluntarily use effective contraceptive measures. * Subjects must voluntarily provide written informed consent. * Upon completion of the run-in period, subjects must meet all of the following three conditions: * At least 4 sexual intercourse attempts were made during the run-in period; ② The failure rate of sexual intercourse attempts was ≥ 50% (failure defined as at least one "No" answer to the first three questions of the Sexual Encounter Profile \[SEP\] diary); ③ The IIEF-Erectile Function (IIEF-EF) domain score was ≥ 5 and ≤ 25. Exclusion Criteria: * \- Subjects with obvious congenital malformations or anatomical abnormalities of the genitalia that significantly impair penile erection. * Subjects with erectile dysfunction caused by other sexual dysfunction disorders (e.g., ejaculatory disorders) or uncontrolled endocrine diseases despite medication (e.g., hypogonadism, hyperthyroidism/hypothyroidism, pituitary tumors). * Subjects with erectile dysfunction resulting from spinal cord injury or radical prostatectomy. * Subjects with a history of penile prosthesis implantation. * Subjects with a history of sudden hearing loss or deafness. * Subjects who have previously failed PDE5 inhibitor therapy for erectile dysfunction. * Subjects with any history of the following cardiac conditions: * Myocardial infarction or stroke within the past 6 months; * Concomitant unstable angina or angina occurring during sexual intercourse; * New York Heart Association (NYHA) Class ≥ II heart failure within the past 6 months; * Concomitant uncontrolled hypertension (≥160/95 mmHg), hypotension (\1.5 times the upper limit of normal (ULN), or those with diabetic complications (diabetic nephropathy, peripheral neuropathy). * Subjects with severe hepatic or renal impairment, defined as AST and/or ALT \>2 × ULN; or creatinine clearance (CrCl) \